balance equationreview2026-07-31
Difference 2307109 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.
Revenue
$0
Fiscal year ended 2026-07-31Operating income
-$1.01M
Fiscal year ended 2026-07-31Free cash flow
Unavailable
Fiscal year ended 2026-07-31PharmaCyte Biotech, Inc. (PMCB) reported revenue of $0 and net income of -$5.08M for the fiscal year ended 2026-07-31. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from PharmaCyte Biotech, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).
Income
| Metric | 2026-07-31 | 2026-04-30 | 2026-01-31 | 2025-10-31 | 2025-07-31 | 2025-04-30 | 2025-01-31 | 2024-10-31 | 2024-07-31 | 2024-04-30 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Gross profit | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Operating income | -$1.01M | -$2.51M | -$2.12M | -$1.38M | -$848.30K | -$1.04M | -$960.25K | -$1.11M | -$1.27M | -$3.17M |
| Net income | -$5.08M | -$4.39M | $746.86K | -$7.42M | -$8.36M | $11.75M | -$3.05M | -$1.47M | $23.42M | $1.35M |
| Research & development | $60.00K | $61.95K | $93.11K | $141.08K | $95.16K | $126.73K | $118.20K | $97.47K | $96.02K | $94.18K |
| Weighted-average diluted shares | shares 10.74M | Unavailable | shares 9.26M | shares 6.80M | shares 6.80M | Unavailable | shares 6.96M | shares 7.64M | shares 7.87M | Unavailable |
| Pretax income | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Income tax expense | $0 | Unavailable | Unavailable | Unavailable | $0 | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Diluted EPS | $-0.54 | Unavailable | $-0.17 | $-1.24 | $-1.23 | Unavailable | $-0.44 | $-0.39 | $1.90 | Unavailable |
| Selling, general & administrative | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| General & administrative | $946.71K | $899.88K | $2.02M | $1.23M | $753.15K | $915.13K | $842.06K | $1.01M | $1.17M | $4.23M |
| Selling & marketing | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
Balance
| Metric | 2026-07-31 | 2026-04-30 | 2026-01-31 | 2025-10-31 | 2025-07-31 | 2025-04-30 | 2025-01-31 | 2024-10-31 | 2024-07-31 | 2024-04-30 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $17.74M | $18.60M | $20.17M | $15.41M | $13.18M | $15.17M | $16.38M | $20.84M | $32.64M | $50.18M |
| Total assets | $36.71M | $46.75M | $55.87M | $55.98M | $45.11M | $55.17M | $43.83M | $55.10M | $70.19M | $59.90M |
| Current assets | $30.97M | $37.42M | $20.70M | $23.02M | $19.11M | $22.38M | $16.96M | $21.33M | $32.88M | $50.44M |
| Total liabilities | $6.90M | $11.77M | $16.47M | $19.42M | $1.52M | $3.28M | $3.58M | $11.65M | $17.15M | $20.39M |
| Current liabilities | $768.68K | $826.42K | $1.68M | $1.58M | $1.06M | $2.91M | $1.19M | $4.78M | $7.47M | $7.42M |
| Total equity incl. NCI | $27.51M | $33.29M | $38.11M | $35.24M | $43.59M | $51.89M | $40.25M | $43.45M | $47.71M | $27.65M |
| Temporary (mezzanine) equity | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Inventory | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Accounts receivable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Goodwill | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Long-term debt | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Accounts payable | $390.54K | $271.10K | $1.20M | $1.02M | $465.21K | $399.20K | $484.95K | $348.60K | $553.95K | $389.37K |
Cash flow
| Metric | 2026-07-31 | 2026-04-30 | 2026-01-31 | 2025-10-31 | 2025-07-31 | 2025-04-30 | 2025-01-31 | 2024-10-31 | 2024-07-31 | 2024-04-30 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$780.89K | -$1.39M | -$786.85K | -$979.52K | -$1.99M | -$1.04M | -$509.89K | -$1.05M | -$373.30K | -$332.96K |
| Capital expenditures | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Investing cash flow | Unavailable | $0 | $5.00M | -$3.00M | $0 | $0 | $0 | $0 | -$7.00M | $0 |
| Financing cash flow | -$83.40K | -$169.82K | $543.78K | $6.21M | $0 | -$171.54K | -$3.95M | -$10.74M | -$10.17M | -$10.70M |
| Net change in cash | -$864.91K | -$1.56M | $4.76M | $2.23M | -$1.99M | -$1.21M | -$4.46M | -$11.80M | -$17.54M | -$11.03M |
| Stock-based compensation | Unavailable | $0 | $771.52K | $60.49K | $60.49K | $0 | -$341.83K | $119.16K | $222.68K | $0 |
| Common dividends paid | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Common share repurchases | Unavailable | $0 | $401.62K | $0 | $0 | $171.54K | $225.02K | $1.40M | $742.18K | $1.17M |
| Depreciation & amortization | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
Derived
| Metric | 2026-07-31 | 2026-04-30 | 2026-01-31 | 2025-10-31 | 2025-07-31 | 2025-04-30 | 2025-01-31 | 2024-10-31 | 2024-07-31 | 2024-04-30 |
|---|---|---|---|---|---|---|---|---|---|---|
| Free cash flow | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Gross margin | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Operating margin | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| FCF margin | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| SBC / revenue | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Current ratio | 40.30x | 45.28x | 12.33x | 14.60x | 18.01x | 7.68x | 14.20x | 4.47x | 4.40x | 6.80x |
| Revenue YoY growth | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Net margin | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| R&D / revenue | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| CapEx / revenue | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Long-term debt / equity | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Effective tax rate | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open PMCB in the interactive workspace to inspect any figure back to its filing.
Source filings
10-Q · Filed 2026-09-14View SEC filing
10-K · Filed 2026-07-29View SEC filing
10-Q · Filed 2026-03-17View SEC filing
10-Q · Filed 2025-12-18View SEC filing
10-Q · Filed 2025-09-15View SEC filing
10-K · Filed 2025-08-11View SEC filing
Reconciliation checks needing review
9 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.
balance equationreview2026-04-30
Difference 1685892 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.
balance equationreview2026-01-31
Difference 1289323 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.
balance equationreview2025-10-31
Difference 1318996 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.
balance equationreview2024-07-31
Difference 5333114 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.
balance equationreview2024-04-30
Difference 11867016 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.
balance equationreview2024-01-31
Difference 17518700 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.
balance equationreview2023-10-31
Difference 21297669 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.
balance equationreview2023-07-31
Difference 20289681 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.